4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vanda Pharmaceuticals Inc. (VNDA) operates in the Biotechnology industry and is headquartered in Washington, United States with about 533 employees. Its market capitalization is roughly $384 million. In the fiscal year ended 2025-12-31, VNDA reported $216M in revenue and ($220M) in net income.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Interactive charts & full statements → Open the VNDA valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $216M | $199M | $193M | $254M |
| Gross Profit | $203M | $188M | $178M | $230M |
| Operating Income (EBIT) | ($151M) | ($41M) | ($14M) | $6M |
| Net Income | ($220M) | ($19M) | $2M | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $52M | $57M | $56M | $53M | $50M |
| Gross Profit | $49M | $53M | $53M | $50M | $46M |
| Operating Income (EBIT) | ($50M) | ($40M) | ($31M) | ($38M) | ($41M) |
| Net Income | ($49M) | ($141M) | ($23M) | ($27M) | ($30M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $489M | $656M | $648M | $634M | — |
| Total Liabilities | $162M | $118M | $104M | $107M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VNDA viewer.
About TickerBase · Data methodology & sources